32 related articles for article (PubMed ID: 10383922)
1. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Nasrin S; Watson CJW; Perez-Paramo YX; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1070-1080. PubMed ID: 34493602
[TBL] [Abstract][Full Text] [Related]
2. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin.
Watkins RE; Maglich JM; Moore LB; Wisely GB; Noble SM; Davis-Searles PR; Lambert MH; Kliewer SA; Redinbo MR
Biochemistry; 2003 Feb; 42(6):1430-8. PubMed ID: 12578355
[TBL] [Abstract][Full Text] [Related]
3. In vitro binding studies with two hypericum perforatum extracts--hyperforin, hypericin and biapigenin--on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters.
Gobbi M; Moia M; Pirona L; Morizzoni P; Mennini T
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S45-8. PubMed ID: 11518075
[TBL] [Abstract][Full Text] [Related]
4. Neurochemical studies with St. John's wort in vitro.
Simmen U; Higelin J; Berger-Büter K; Schaffner W; Lundstrom K
Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S137-42. PubMed ID: 11518063
[TBL] [Abstract][Full Text] [Related]
5. Determination of the new morpholino anthracycline MX2.HCl and its metabolites in biological samples by high-performance liquid chromatography.
Shinkai H; Takahashi H; Kikuchi K; Kawai H; Otake N
J Chromatogr; 1991 Sep; 570(1):203-8. PubMed ID: 1797829
[TBL] [Abstract][Full Text] [Related]
6. Sucralose, a synthetic organochlorine sweetener: overview of biological issues.
Schiffman SS; Rother KI
J Toxicol Environ Health B Crit Rev; 2013; 16(7):399-451. PubMed ID: 24219506
[TBL] [Abstract][Full Text] [Related]
7. [Cytochrome P450 isoenzymes in metabolism of endo- and exogenic compounds].
Wiśniewska A; Mazerska Z
Postepy Biochem; 2009; 55(3):259-71. PubMed ID: 19928582
[TBL] [Abstract][Full Text] [Related]
8. The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo.
Sychev DA; Ashraf GM; Svistunov AA; Maksimov ML; Tarasov VV; Chubarev VN; Otdelenov VA; Denisenko NP; Barreto GE; Aliev G
Drug Des Devel Ther; 2018; 12():1147-1156. PubMed ID: 29780235
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
Katoh M; Nakajima M; Shimada N; Yamazaki H; Yokoi T
Eur J Clin Pharmacol; 2000; 55(11-12):843-52. PubMed ID: 10805063
[TBL] [Abstract][Full Text] [Related]
11. Inhibition and inactivation of human cytochrome P450 isoforms by phenethyl isothiocyanate.
Nakajima M; Yoshida R; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 2001 Aug; 29(8):1110-3. PubMed ID: 11454729
[TBL] [Abstract][Full Text] [Related]
12. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs.
Nakajima M; Nakamura S; Tokudome S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Dec; 27(12):1381-91. PubMed ID: 10570018
[TBL] [Abstract][Full Text] [Related]
13. Effects of etodolac on P450 isoform-specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Zinno A; Nonaka K; Mukai H
Arzneimittelforschung; 2005; 55(12):744-8. PubMed ID: 16430028
[TBL] [Abstract][Full Text] [Related]
14. In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine.
Imai T; Taketani M; Suzu T; Kusube K; Otagiri M
Drug Metab Dispos; 1999 Aug; 27(8):942-6. PubMed ID: 10421623
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
